lopinavir/ritonavir - for COVID-19 severe or critically method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.71 [0.36, 1.40]< 10%1 study (1 / -)83.8 %some concernnot evaluable moderatecrucial-
clinical improvement 1.31 [0.94, 1.83]> 10%1 study (1 / -)94.4 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.59 [0.84, 3.03]> 10%1 study (1 / -)92.1 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.31 [0.94, 1.83]> 10%1 study (1 / -)94.4 %some concernnot evaluable moderateimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 1 pathologies: 91 91